Literature DB >> 33255269

A Representative GIIA Phospholipase A2 Activates Preadipocytes to Produce Inflammatory Mediators Implicated in Obesity Development.

Elbio Leiguez1, Priscila Motta1, Rodrigo Maia Marques1, Bruno Lomonte2, Suely Vilela Sampaio3, Catarina Teixeira1.   

Abstract

Adipose tissue secretes proinflammatory mediators which promote systemic and adipose tissue inflammation seen in obesity. Group IIA (GIIA)-secreted phospholipase A2 (sPLA2) enzymes are found to be elevated in plasma and adipose tissue from obese patients and are active during inflammation, generating proinflammatory mediators, including prostaglandin E2 (PGE2). PGE2 exerts anti-lipolytic actions and increases triacylglycerol levels in adipose tissue. However, the inflammatory actions of GIIA sPLA2s in adipose tissue cells and mechanisms leading to increased PGE2 levels in these cells are unclear. This study investigates the ability of a representative GIIA sPLA2, MT-III, to activate proinflammatory responses in preadipocytes, focusing on the biosynthesis of prostaglandins, adipocytokines and mechanisms involved in these effects. Our results showed that MT-III induced biosynthesis of PGE2, PGI2, MCP-1, IL-6 and gene expression of leptin and adiponectin in preadipocytes. The MT-III-induced PGE2 biosynthesis was dependent on cytosolic PLA2 (cPLA2)-α, cyclooxygenases (COX)-1 and COX-2 pathways and regulated by a positive loop via the EP4 receptor. Moreover, MT-III upregulated COX-2 and microsomal prostaglandin synthase (mPGES)-1 protein expression. MCP-1 biosynthesis induced by MT-III was dependent on the EP4 receptor, while IL-6 biosynthesis was dependent on EP3 receptor engagement by PGE2. These data highlight preadipocytes as targets for GIIA sPLA2s and provide insight into the roles played by this group of sPLA2s in obesity.

Entities:  

Keywords:  EP receptors; adipokines; cytokines; phospholipase A2; preadipocytes; prostaglandins

Year:  2020        PMID: 33255269      PMCID: PMC7760919          DOI: 10.3390/biom10121593

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  88 in total

Review 1.  Regulation of leptin release by mammalian adipose tissue.

Authors:  J N Fain; S W Bahouth
Journal:  Biochem Biophys Res Commun       Date:  2000-08-11       Impact factor: 3.575

Review 2.  Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach.

Authors:  Jaismy Jacob P; S L Manju; K R Ethiraj; Geetha Elias
Journal:  Eur J Pharm Sci       Date:  2018-06-05       Impact factor: 4.384

3.  NS-398, a selective COX-2 inhibitor, inhibits proliferation of IL-1beta-stimulated vascular smooth muscle cells by induction of HO-1.

Authors:  Hyoung Chul Choi; Hee Sun Kim; Kwang Youn Lee; Ki Churl Chang; Young Jin Kang
Journal:  Biochem Biophys Res Commun       Date:  2008-09-20       Impact factor: 3.575

Review 4.  Adipose tissue changes in obesity and the impact on metabolic function.

Authors:  Susan Sam; Theodore Mazzone
Journal:  Transl Res       Date:  2014-05-24       Impact factor: 7.012

Review 5.  Secreted phospholipase A2 revisited.

Authors:  Makoto Murakami; Yoshitaka Taketomi; Hiroyasu Sato; Kei Yamamoto
Journal:  J Biochem       Date:  2011-07-11       Impact factor: 3.387

6.  Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway.

Authors:  M Murakami; T Kambe; S Shimbara; S Yamamoto; H Kuwata; I Kudo
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

7.  Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts.

Authors:  Fumiaki Kojima; Hiroaki Naraba; Yasuharu Sasaki; Moroe Beppu; Haruhito Aoki; Shinichi Kawai
Journal:  Arthritis Rheum       Date:  2003-10

8.  Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDL.

Authors:  M-E Paradis; M-O Hogue; J-F Mauger; C Couillard; P Couture; N Bergeron; B Lamarche
Journal:  Int J Obes (Lond)       Date:  2006-03-14       Impact factor: 5.095

Review 9.  Properties and functions of adipose tissue macrophages in obesity.

Authors:  Lucia Russo; Carey N Lumeng
Journal:  Immunology       Date:  2018-10-19       Impact factor: 7.397

10.  Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.

Authors:  Jianxiong Jiang; Ray Dingledine
Journal:  J Pharmacol Exp Ther       Date:  2012-11-28       Impact factor: 4.030

View more
  5 in total

1.  Biological Evaluation, Molecular Docking Analyses, and ADME Profiling of Certain New Quinazolinones as Anti-colorectal Agents.

Authors:  Nahed N E El-Sayed; Norah M Almaneai; Abir Ben Bacha; Mohamed K El-Ashrey; Maha I Al-Zaben; Zainab M Almarhoon
Journal:  ACS Omega       Date:  2022-05-23

2.  Metabolomics in early life and the association with body composition at age 2 years.

Authors:  Inge A L P van Beijsterveldt; Stuart G Snowden; Pernille Neve Myers; Kirsten S de Fluiter; Bert van de Heijning; Susanne Brix; Ken K Ong; David B Dunger; Anita C S Hokken-Koelega; Albert Koulman
Journal:  Pediatr Obes       Date:  2021-10-13       Impact factor: 3.910

3.  Bothrops moojeni snake venom induces an inflammatory response in preadipocytes: Insights into a new aspect of envenomation.

Authors:  Rodrigo Maia-Marques; Danilo Santos Teixeira; Priscila Motta Janovits; Carlos DeOcesano-Pereira; Elbio Leiguez; Catarina Teixeira
Journal:  PLoS Negl Trop Dis       Date:  2022-08-08

4.  Phospholipases: From Structure to Biological Function.

Authors:  María A Balboa; Jesús Balsinde
Journal:  Biomolecules       Date:  2021-03-15

Review 5.  Inflammatory Effects of Bothrops Phospholipases A2: Mechanisms Involved in Biosynthesis of Lipid Mediators and Lipid Accumulation.

Authors:  Vanessa Moreira; Elbio Leiguez; Priscila Motta Janovits; Rodrigo Maia-Marques; Cristina Maria Fernandes; Catarina Teixeira
Journal:  Toxins (Basel)       Date:  2021-12-04       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.